Updated July 2026 · 9 min read

Cisatracurium (Nimbex) for ICU Nurses 2026

Part of the ICU Emergencies Hub — browse every related guide in one place.

Cisatracurium is the paralytic you're most likely to see running as a continuous infusion in the ICU — not for intubation, but for sustained neuromuscular blockade in severe respiratory failure. Its defining feature is how it's cleared from the body, which makes it uniquely suited to the sickest patients whose kidneys and liver are failing.

When it's used

The signature ICU indication is severe ARDS: in carefully selected patients with a low P/F ratio early in the course, a continuous paralytic can improve ventilator synchrony, reduce barotrauma, and lower the work of breathing when deep sedation alone isn't enough. Cisatracurium is also used to facilitate lung-protective ventilation, to control refractory intracranial or intra-abdominal pressure, during therapeutic hypothermia to stop shivering, and in other situations where any patient movement or vent dyssynchrony is dangerous. It is not a first-line intubating agent — that's rocuronium or succinylcholine.

The absolute rule: sedate and provide analgesia first

Train-of-four monitoring

Continuous paralysis is titrated to a goal, and the standard bedside tool is train-of-four (TOF) peripheral nerve stimulation. Four small electrical stimuli are delivered over a nerve (commonly the ulnar nerve at the wrist) and you count the number of muscle twitches. Fewer twitches means deeper blockade. A common target is one or two out of four twitches — enough to achieve the clinical goal while avoiding total, prolonged blockade that risks accumulation and prolonged weakness. Dosing the drip purely by twitches, however, has limits, so many units combine TOF with clinical goals (vent synchrony, plateau pressures).

Dosing and monitoring pearls

Cisatracurium is usually given as a bolus to establish blockade followed by a weight-based continuous infusion titrated to TOF and clinical effect. Because it's Hofmann-eliminated, its offset is relatively predictable once stopped, and it doesn't rely on organ function to clear. Beyond TOF, the bedside nurse watches for adequate sedation depth, protects the eyes (paralyzed patients can't blink — lubricate and tape to prevent corneal abrasion), ensures DVT prophylaxis and pressure-injury prevention (an immobile patient is high-risk for both), and confirms alarms and ventilator settings are meticulous because the patient cannot breathe on their own or trigger a distress response.

The big long-term risk: ICU-acquired weakness

Prolonged neuromuscular blockade — especially combined with corticosteroids and critical illness — is associated with ICU-acquired weakness and prolonged recovery. This is a key reason blockade is targeted to the lightest effective level (hence the one-to-two-twitch goal rather than zero), used for the shortest necessary duration, and reassessed daily for whether it can be stopped. Cisatracurium is often preferred over aminosteroid paralytics like vecuronium partly because its organ-independent clearance reduces the accumulation that can worsen this weakness.

Related: rocuronium vs vecuronium, cisatracurium vs succinylcholine, propofol guide, and ICU sepsis guide.

This article is general educational information for licensed clinicians and students, not medical advice or a substitute for your institution's protocols, pharmacy guidance, or a provider's orders. Always follow facility policy and verify doses independently.